cyclohexanol has been researched along with Parkinsonian Disorders in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ardashov, O; Ivanova, Е; Kapitsa, I; Khazanov, V; Salakhutdinov, N; Valdman, E; Volcho, K; Voronina, TI | 1 |
Alexander, M; Burton, NC; Griswold, M; Guilarte, TR; McGlothan, JL; Pham, L; Schneider, JS; Syversen, T; Verina, T; Wong, DF; Zhou, Y | 1 |
Ardashov, OV; Il'ina, IV; Karpova, EV; Korchagina, DV; Morozova, EA; Pavlova, AV; Salakhutdinov, NF; Tolstikova, TG; Volcho, KP | 1 |
Bari, M; Battista, N; Bernardi, G; Calabresi, P; Centonze, D; Finazzi-Agrò, A; Gubellini, P; Maccarrone, M; Picconi, B | 1 |
4 other study(ies) available for cyclohexanol and Parkinsonian Disorders
Article | Year |
---|---|
Evolution of anti-parkinsonian activity of monoterpenoid (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in various in vivo models.
Topics: Animals; Antiparkinson Agents; Catalepsy; Cyclohexanols; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Oxotremorine; Parkinsonian Disorders; Reserpine | 2017 |
Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism.
Topics: Amphetamine; Animals; Cocaine; Corpus Striatum; Cyclohexanols; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Image Processing, Computer-Assisted; Macaca fascicularis; Male; Manganese; Parkinsonian Disorders; Positron-Emission Tomography; Substantia Nigra; Synaptic Transmission; Tetrabenazine; Tyrosine 3-Monooxygenase | 2008 |
Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclohexanols; Disease Models, Animal; Dopamine Antagonists; Drug Synergism; Haloperidol; Levodopa; Mice; Mice, Inbred C57BL; Molecular Conformation; Motor Activity; Neurotoxins; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Neurotransmitter; Stereoisomerism | 2011 |
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism.
Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Binding, Competitive; Cannabinoid Receptor Modulators; Cerebellum; Corpus Striatum; Cyclohexanols; Disease Models, Animal; Endocannabinoids; Excitatory Postsynaptic Potentials; Fatty Acids, Unsaturated; Glutamic Acid; Glycerides; In Vitro Techniques; Levodopa; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Phospholipase D; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug | 2003 |